Compare Novo Nordisk A/S (NVO) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Packaging Corporation of America — how do they compare? Novo Nordisk A/S trades at $38.16 (market cap $165.31B), while Packaging Corporation of America trades at $231.22 (market cap $20.49B). The key difference: Novo Nordisk A/S is far larger — about 8.1× Packaging Corporation of America's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Packaging Corporation of America for 45 Days on average.
| NVO | PKG | |
|---|---|---|
Market Cap | $165.31B | $20.49B |
Volume | 11,432,838 | 493,499 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $257.43 |
52-Week Low | $35.29 | $191.68 |
Typical Hold Time | 116 Days | 45 Days |
Enterprise Value | $179.56B | $24.30B |
Dividend Yield | 4.71% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Packaging Corporation of America (PKG) trades at $227.25, down 1.08% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with Q2 2026 beating estimates but net income margin projected to decline in 2026. Analyst consensus is a Buy with a $272.43 price target, though technical indicators suggest near-term pressure with support at $225.
PKG offers a stable dividend and benefits from consistent packaging demand, but faces headwinds from cost pressures and negative cash flow. Investment appeal hinges on execution against margin challenges and the upcoming Q3 earnings report. Risks include rising input costs and competitive pressures in the industrial packaging sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
